For patients with triple negative breast cancer (TNBC), characterized by lack of expression of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor-2 (HER-2) amplification, chemotherapy remains the chief systemic treatment option because specific endocrine and molecular targets are unavailable (1). Here, ESR1 is linked to triple-negative breast carcinoma.